Cargando…
Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee
Recently, platelet-rich plasma (PRP) has received attention as a treatment for patients with osteoarthritis of the knee (OAK), a chronic degenerative disease, to bridge the gap between conservative and surgical treatments. Here, we investigated the differences in the humoral factors present in two t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324396/ https://www.ncbi.nlm.nih.gov/pubmed/32601400 http://dx.doi.org/10.1038/s41598-020-67099-y |
_version_ | 1783551932904767488 |
---|---|
author | Wasai, Shiho Sato, Masato Maehara, Miki Toyoda, Eriko Uchiyama, Ryoka Takahashi, Takumi Okada, Eri Iwasaki, Yoshiko Suzuki, Satoko Watanabe, Masahiko |
author_facet | Wasai, Shiho Sato, Masato Maehara, Miki Toyoda, Eriko Uchiyama, Ryoka Takahashi, Takumi Okada, Eri Iwasaki, Yoshiko Suzuki, Satoko Watanabe, Masahiko |
author_sort | Wasai, Shiho |
collection | PubMed |
description | Recently, platelet-rich plasma (PRP) has received attention as a treatment for patients with osteoarthritis of the knee (OAK), a chronic degenerative disease, to bridge the gap between conservative and surgical treatments. Here, we investigated the differences in the humoral factors present in two types of PRP purified using the Autologous Protein Solution (APS) kit (group Z; leucocyte-rich PRP) or the Cellaid Serum Collection Set P type (group J; leucocyte-poor [LP]-PRP). Differences in humoral factors between healthy subjects (n = 10) and OAK patients (n = 12; group Z = 6, group J = 6), and the relationship between humoral factors and clinical outcome scores were investigated. Both anti-inflammatory and inflammatory cytokines were highly enriched in APS. The concentrations of tumour necrosis factor (TNF)-α, platelet-derived growth factor, fibroblast growth factor, soluble TNF-receptor 2, soluble Fas and transforming growth factor-β1 were higher in group Z, while the total amounts were higher in group J. The concentration of interleukin-1 receptor antagonist was positively correlated with the magnitude of change in the clinical outcome score and may contribute to improving knee-joint function. This is the first description of the humoral factors in APS and LP-PRP prepared from healthy subjects or OAK patients of Asian descent. |
format | Online Article Text |
id | pubmed-7324396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73243962020-06-30 Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee Wasai, Shiho Sato, Masato Maehara, Miki Toyoda, Eriko Uchiyama, Ryoka Takahashi, Takumi Okada, Eri Iwasaki, Yoshiko Suzuki, Satoko Watanabe, Masahiko Sci Rep Article Recently, platelet-rich plasma (PRP) has received attention as a treatment for patients with osteoarthritis of the knee (OAK), a chronic degenerative disease, to bridge the gap between conservative and surgical treatments. Here, we investigated the differences in the humoral factors present in two types of PRP purified using the Autologous Protein Solution (APS) kit (group Z; leucocyte-rich PRP) or the Cellaid Serum Collection Set P type (group J; leucocyte-poor [LP]-PRP). Differences in humoral factors between healthy subjects (n = 10) and OAK patients (n = 12; group Z = 6, group J = 6), and the relationship between humoral factors and clinical outcome scores were investigated. Both anti-inflammatory and inflammatory cytokines were highly enriched in APS. The concentrations of tumour necrosis factor (TNF)-α, platelet-derived growth factor, fibroblast growth factor, soluble TNF-receptor 2, soluble Fas and transforming growth factor-β1 were higher in group Z, while the total amounts were higher in group J. The concentration of interleukin-1 receptor antagonist was positively correlated with the magnitude of change in the clinical outcome score and may contribute to improving knee-joint function. This is the first description of the humoral factors in APS and LP-PRP prepared from healthy subjects or OAK patients of Asian descent. Nature Publishing Group UK 2020-06-29 /pmc/articles/PMC7324396/ /pubmed/32601400 http://dx.doi.org/10.1038/s41598-020-67099-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Wasai, Shiho Sato, Masato Maehara, Miki Toyoda, Eriko Uchiyama, Ryoka Takahashi, Takumi Okada, Eri Iwasaki, Yoshiko Suzuki, Satoko Watanabe, Masahiko Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee |
title | Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee |
title_full | Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee |
title_fullStr | Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee |
title_full_unstemmed | Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee |
title_short | Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee |
title_sort | characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324396/ https://www.ncbi.nlm.nih.gov/pubmed/32601400 http://dx.doi.org/10.1038/s41598-020-67099-y |
work_keys_str_mv | AT wasaishiho characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee AT satomasato characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee AT maeharamiki characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee AT toyodaeriko characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee AT uchiyamaryoka characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee AT takahashitakumi characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee AT okadaeri characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee AT iwasakiyoshiko characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee AT suzukisatoko characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee AT watanabemasahiko characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee |